BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1493 related articles for article (PubMed ID: 36248822)

  • 1. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
    Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
    BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
    Chen X; Hu G; Xiong L; Xu Q
    Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
    [No Abstract]   [Full Text] [Related]  

  • 10. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy.
    Wang G; Xiao R; Zhao S; Sun L; Guo J; Li W; Zhang Y; Bian X; Qiu W; Wang S
    Front Immunol; 2022; 13():945516. PubMed ID: 36248857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
    Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
    Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of a novel cuproptosis-related gene signature for predicting prognosis and estimating tumor immune microenvironment status in papillary thyroid carcinoma.
    Wang L; Yao B; Yang J; Tian Z; He J
    BMC Cancer; 2022 Nov; 22(1):1131. PubMed ID: 36333684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma.
    Zhang Z; Zeng X; Wu Y; Liu Y; Zhang X; Song Z
    Front Immunol; 2022; 13():925618. PubMed ID: 35898502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
    Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
    Front Genet; 2023; 14():1056000. PubMed ID: 36845390
    [No Abstract]   [Full Text] [Related]  

  • 16. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
    Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
    Front Immunol; 2022; 13():991604. PubMed ID: 36685508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC.
    Qin H; Sheng W; Zhang G; Yang Q; Yao S; Yue Y; Zhang P; Zhu Y; Wang Q; Chen Y; Zeng H; Weng J; Yu F; Yang J
    Front Genet; 2023; 14():1094793. PubMed ID: 36891150
    [No Abstract]   [Full Text] [Related]  

  • 18. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
    Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
    Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cuproptosis-related prognostic signatures predict the prognosis and immunotherapy in HCC patients.
    Peng H; Zou Z; Xiang Z; Lu X; Zhang Y; Peng X
    Medicine (Baltimore); 2023 Aug; 102(34):e34741. PubMed ID: 37653738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma.
    Li Y; Zeng X
    Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 75.